Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: big pharma and Ukraine; new gene therapy deal for Novartis; Phase III hemophilia success for Sanofi; J&J’s Gorsky’s views on Asia innovation; and a look at pharma’s deal-making activity last year.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 11 March 2022, including: big pharma and Ukraine; new gene therapy deal for Novartis AG; Phase III hemophilia success for Sanofi; Johnson & Johnson’s Gorsky’s views on Asia innovation; and a look at pharma’s deal-making activity last year.
This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Big Pharma Braces For Modest Financial And Clinical Trial Disruption In Eastern Europe" - Scrip, 9 Mar, 2022.)
(Also see "Novartis Bets Big On Next-Gen Gene Therapy With Voyager Pact" - Scrip, 8 Mar, 2022.)
(Also see "Sanofi Looks To Dominate $5bn Hemophilia A Factor Market After Trial Success" - Scrip, 9 Mar, 2022.)
(Also see "J&J’s Gorsky Puts Spotlight On Big Picture Potential Of Asia, New Technologies" - Scrip, 7 Mar, 2022.)
(Also see "Who Were Big Pharma's Top Deal-Makers In 2021?" - Scrip, 4 Mar, 2022.)